{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:20:19Z","timestamp":1794745219250,"version":"4.9.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR - M4C2-I1.3 Project PE_00000019 \\\"HEAL ITALIA"],"award-info":[{"award-number":["PNRR - M4C2-I1.3 Project PE_00000019 \\\"HEAL ITALIA"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119956","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:19:19Z","timestamp":1790385559000},"page":"119956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma"],"prefix":"10.1016","volume":"204","author":[{"given":"Davide","family":"Busato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-7460","authenticated-orcid":false,"given":"Monica","family":"Argenziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Polano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Capolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mossenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Tangredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mangogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Durigutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Sblattero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3079-4019","authenticated-orcid":false,"given":"Paolo","family":"Macor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Dal","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119956_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer Journal Clinicians"},{"key":"10.1016\/j.biopha.2026.119956_bib2","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.21873\/anticanres.13026","article-title":"Targeted therapies for pancreatic cancer and hurdles ahead","volume":"38","author":"Aslan","year":"2018","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.biopha.2026.119956_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.688377","article-title":"The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy","volume":"11","author":"Principe","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119956_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","author":"Tran","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119956_bib5","series-title":"Natural Polymer Drug Delivery Systems: Nanoparticles, Plants, and Algae","first-page":"33","article-title":"Nanoparticles Types, Classification, Characterization, Fabrication Methods and Drug Delivery Applications","author":"Bhatia","year":"2016"},{"key":"10.1016\/j.biopha.2026.119956_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119956_bib7","doi-asserted-by":"crossref","first-page":"12320","DOI":"10.1002\/anie.201403036","article-title":"Engineered nanoparticles for drug delivery in cancer therapy","volume":"53","author":"Sun","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2026.119956_bib8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jpm11080771","article-title":"The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application","volume":"11","author":"Wu","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2026.119956_bib9","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/pharmaceutics13101538","article-title":"Developing Actively Targeted Nanoparticles to Fight Cancer: Focus on Italian Research","volume":"13","author":"Argenziano","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119956_bib10","first-page":"1621","article-title":"Potential and problems in ultrasound-responsive drug delivery systems","volume":"8","author":"Zhao","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119956_bib11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.7150\/thno.37593","article-title":"Micro\/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications","volume":"10","author":"Duan","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2026.119956_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225776","article-title":"Synthesis, Bioapplications, and Toxicity Evaluation of Chitosan-Based Nanoparticles","volume":"20","author":"Rizeq","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119956_bib13","article-title":"Chitosan Derivatives and Their Application in Biomedicine","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119956_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9040053","article-title":"An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery","volume":"9","author":"Mohammed","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119956_bib15","first-page":"1","article-title":"The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells","author":"Di Cintio","year":"2024","journal-title":"Nanomed. (Lond. )"},{"key":"10.1016\/j.biopha.2026.119956_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/17435889.2025.2452154","article-title":"Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma","volume":"20","author":"Mossenta","year":"2025","journal-title":"Nanomed. (Lond. )"},{"key":"10.1016\/j.biopha.2026.119956_bib17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119956_bib18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1172\/JCI4105","article-title":"The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer","volume":"102","author":"Kleeff","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119956_bib19","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1002\/cam4.1833","article-title":"High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma","volume":"7","author":"Zhou","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.biopha.2026.119956_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature14581","article-title":"Glypican-1 identifies cancer exosomes and detects early pancreatic cancer","volume":"523","author":"Melo","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119956_bib21","doi-asserted-by":"crossref","first-page":"24741","DOI":"10.18632\/oncotarget.15799","article-title":"Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma","volume":"8","author":"Harada","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119956_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-030-40146-7_8","article-title":"The Role of Glypican-1 in the Tumour Microenvironment","volume":"1245","author":"Lund","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.biopha.2026.119956_bib23","doi-asserted-by":"crossref","first-page":"22991","DOI":"10.1074\/jbc.M115.660878","article-title":"Structural Aspects of N-Glycosylations and the C-terminal Region in Human Glypican-1","volume":"290","author":"Awad","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119956_bib24","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-21-0335","article-title":"Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer","author":"Tsujii","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119956_bib25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1186\/s12967-023-04745-9","article-title":"A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Busato","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119956_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4155\/tde.15.92","article-title":"Nanobubbles: a promising efficient tool for therapeutic delivery","volume":"7","author":"Cavalli","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.biopha.2026.119956_bib27","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/jbm.a.32470","article-title":"Targeted molecular imaging of VEGF receptors overexpressed in ischemic microvasculature using chitosan-DC101 conjugates","volume":"92","author":"Lee","year":"2010","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.biopha.2026.119956_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1200310","article-title":"Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models","volume":"14","author":"Capolla","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119956_bib29","first-page":"319","article-title":"Body condition scoring: a rapid and accurate method for assessing health status in mice","volume":"49","author":"Ullman-Culler\u00e9","year":"1999","journal-title":"Lab. Anim. Sci."},{"key":"10.1016\/j.biopha.2026.119956_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nbt.3820","article-title":"Nextflow enables reproducible computational workflows","volume":"35","author":"Di Tommaso","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119956_bib31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119956_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5858\/arpa.2011-0689-RA","article-title":"Approach to intraoperative consultation for donor liver biopsies","volume":"137","author":"Melin","year":"2013","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.biopha.2026.119956_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/ajt.13929","article-title":"Banff Working Group, Banff Histopathological Consensus Criteria for Preimplantation Kidney Biopsies","volume":"17","author":"Liapis","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.biopha.2026.119956_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jcp.2005.026443","article-title":"An approach to endomyocardial biopsy interpretation","volume":"59","author":"Cunningham","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.biopha.2026.119956_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00428-013-1430-4","article-title":"Diagnostic use of the endomyocardial biopsy: a consensus statement","volume":"463","author":"Thiene","year":"2013","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2026.119956_bib36","doi-asserted-by":"crossref","first-page":"888","DOI":"10.14348\/molcells.2014.0207","article-title":"Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines","volume":"37","author":"Kim","year":"2014","journal-title":"Mol. Cells"},{"key":"10.1016\/j.biopha.2026.119956_bib37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/thy.2015.0342","article-title":"Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer","volume":"26","author":"Marano","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.biopha.2026.119956_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2026.119956_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119956_bib40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/cancers13040799","article-title":"Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology","volume":"13","author":"Leroux","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119956_bib41","first-page":"33","article-title":"Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy","volume":"13","author":"Cruz","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.biopha.2026.119956_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1172\/JCI32412","article-title":"Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells","volume":"118","author":"Aikawa","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119956_bib43","doi-asserted-by":"crossref","first-page":"99552","DOI":"10.18632\/oncotarget.20601","article-title":"EVI1 modulates oncogenic role of GPC1 in pancreatic carcinogenesis","volume":"8","author":"Tanaka","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119956_bib44","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3389\/fimmu.2018.02203","article-title":"Complement as a Biological Tool to Control Tumor Growth","volume":"9","author":"Macor","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119956_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.imlet.2007.04.014","article-title":"Complement as effector system in cancer immunotherapy","volume":"111","author":"Macor","year":"2007","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.biopha.2026.119956_bib46","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.4049\/jimmunol.1601473","article-title":"Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms","volume":"198","author":"Cleary","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2026.119956_bib47","doi-asserted-by":"crossref","unstructured":"M. Argenziano, S. Occhipinti, A. Scomparin, C. Angelini, F. Novelli, M. Soster, M. Giovarelli, R. Cavalli, Exploring Chitosan-Shelled Nanobubbles to Improve HER2+ Immunotherapy Through Dendritic Cells Targeting, (2021). https:\/\/doi.org\/10.21203\/rs.3.rs-787377\/v1.","DOI":"10.21203\/rs.3.rs-787377\/v1"},{"key":"10.1016\/j.biopha.2026.119956_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s11671-019-2853-x","article-title":"Biocompatible Chitosan Nanobubbles for Ultrasound-Mediated Targeted Delivery of Doxorubicin","volume":"14","author":"Zhou","year":"2019","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.biopha.2026.119956_bib49","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1007\/s00216-016-9641-6","article-title":"Evaluation of cytotoxicity profile and intracellular localisation of doxorubicin-loaded chitosan nanoparticles","volume":"408","author":"Souto","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.biopha.2026.119956_bib50","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/pharmaceutics17121530","article-title":"Exploring Anti-Neoplastic Activity of Chitosan Nanobubbles Decorated with ICOS-Fc and Loaded with Paclitaxel in a Human and Murine Model of Melanoma","volume":"17","author":"Pantham","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119956_bib51","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.3390\/ijms21114118","article-title":"Mouse Tumor Models for Advanced Cancer Immunotherapy","volume":"21","author":"Chulpanova","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119956_bib52","doi-asserted-by":"crossref","unstructured":"M.V. Guerin, V. Finisguerra, B.J. Van den Eynde, N. Bercovici, A. Trautmann, Preclinical murine tumor models: A structural and functional perspective, eLife 9 (n.d.) e50740. https:\/\/doi.org\/10.7554\/eLife.50740.","DOI":"10.7554\/eLife.50740"},{"key":"10.1016\/j.biopha.2026.119956_bib53","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12885-015-1091-6","article-title":"The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts","volume":"15","author":"Fung","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119956_bib54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrc.2017.92","article-title":"Preclinical mouse solid tumour models: status quo, challenges and perspectives","volume":"17","author":"Gengenbacher","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119956_bib55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119956_bib56","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/cancers12051327","article-title":"Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models","volume":"12","author":"Garcia","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119956_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114872","article-title":"A common control group - optimising the experiment design to maximise sensitivity","volume":"9","author":"Bate","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119956_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.202200061","article-title":"Statistical review of animal trials-A guideline","volume":"65","author":"Piper","year":"2023","journal-title":"Biom. J."},{"key":"10.1016\/j.biopha.2026.119956_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijo.2026.5848","article-title":"Unveiling sex differences in pancreatic ductal adenocarcinoma: current evidence and future directions (Review)","volume":"68","author":"Rauschenberg","year":"2026","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2026.119956_bib60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/leu.2014.185","article-title":"Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice","volume":"29","author":"Macor","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2026.119956_bib61","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2310\/7290.2008.00028","article-title":"vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging","volume":"7","author":"Biffi","year":"2008","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.biopha.2026.119956_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799910","article-title":"Single-domain antibodies for targeting, detection, and in vivo imaging of human CD4+ cells","volume":"12","author":"Traenkle","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119956_bib63","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cyto.a.20419","article-title":"vivo imaging in experimental preclinical tumor research--a review","volume":"71","author":"Wessels","year":"2007","journal-title":"Cytom. A"},{"key":"10.1016\/j.biopha.2026.119956_bib64","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4638192","article-title":"The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target","volume":"2020","author":"Baboci","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.biopha.2026.119956_bib65","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17425247.2024.2375400","article-title":"Understanding nanoparticle-liver interactions in nanomedicine","volume":"21","author":"He","year":"2024","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"10.1016\/j.biopha.2026.119956_bib66","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.2147\/IJN.S208496","article-title":"Co-disposition of chitosan nanoparticles by multi types of hepatic cells and their subsequent biological elimination: the mechanism and kinetic studies at the cellular and animal levels","volume":"14","author":"Jiang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2026.119956_bib67","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ki.2008.260","article-title":"Glomerular filtration: the charge debate charges ahead","volume":"74","author":"Miner","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2026.119956_bib68","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/jps.10129","article-title":"Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats","volume":"91","author":"Zara","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119956_bib69","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/CAD.0b013e328304d948","article-title":"Reduced uptake of liposomal idarubicin in the perfused rat heart","volume":"19","author":"Sermsappasuk","year":"2008","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.biopha.2026.119956_bib70","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.actbio.2022.12.004","article-title":"Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma","volume":"157","author":"Zheng","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biopha.2026.119956_bib71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/ERC-17-0045","article-title":"Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model","volume":"24","author":"Marano","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2026.119956_bib72","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1021\/acs.biomac.7b01297","article-title":"siRNA delivery with chitosan: influence of chitosan molecular weight, degree of deacetylation, and amine to phosphate ratio on in vitro silencing efficiency, hemocompatibility, biodistribution, and in vivo efficacy","volume":"19","author":"Alameh","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biopha.2026.119956_bib73","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3390\/md17060381","article-title":"Recent advances in chitosan-based carriers for gene delivery","volume":"17","author":"Cao","year":"2019","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.biopha.2026.119956_bib74","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/molecules26020272","article-title":"Chitosan nanoparticles-insight into properties, functionalization and applications in drug delivery and theranostics","volume":"26","author":"Jhaveri","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119956_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116255","article-title":"Glycol chitosan-based renal docking biopolymeric nanomicelles for site-specific delivery of the immunosuppressant","volume":"241","author":"Kim","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2026.119956_bib76","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-3835(97)00326-1","article-title":"Anti-HER2 immunoliposomes for targeted therapy of human tumors","volume":"118","author":"Park","year":"1997","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119956_bib77","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3762\/bjnano.14.75","article-title":"Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics","volume":"14","author":"Kumari","year":"2023","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119956_bib78","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1039\/D1MA00225B","article-title":"Anti-GPC1-modified mesoporous silica nanoparticles as nanocarriers for combination therapy and targeting of PANC-1 cells","volume":"2","author":"Estev\u00e3o","year":"2021","journal-title":"Mater. Adv."},{"key":"10.1016\/j.biopha.2026.119956_bib79","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-08-2392","article-title":"Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody","volume":"15","author":"ElBayoumi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119956_bib80","article-title":"For and against tumor microenvironment: nanoparticle-based strategies for active cancer therapy","volume":"31","author":"Karimi","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biopha.2026.119956_bib81","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119956_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10325","article-title":"Chitosan-based nanoscale systems for doxorubicin delivery: exploring biomedical application in cancer therapy","volume":"8","author":"Ashrafizadeh","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119956_bib83","doi-asserted-by":"crossref","first-page":"C846","DOI":"10.1152\/ajpcell.00290.2021","article-title":"Role of glypican-1 in regulating multiple cellular signaling pathways","volume":"321","author":"Pan","year":"2021","journal-title":"Am. J. Physiol. Cell. Physiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:03:43Z","timestamp":1794744223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":83,"alternative-id":["S0753332226009923"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119956","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119956"}}